AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01851148 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: triptans
Description: administration of triptans drug treatment according to international guidelines
Study NCT01851148 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: triptans
Description: administration of triptans drug treatment according to international guidelines
Study NCT00892827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)
Description: Rituximab (375 mg/m2) with FFP will be given every two weeks
Study NCT01159327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400mg, bid(800mg/day), daily, PO
Study NCT01460927 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TriActive+ RF
Description: Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts.
Study NCT02495610 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gait analysis and MRI:
Description: * Gait analysis: Treadmill with pressure sensors (FDM-THM-M-System; 'Zebris' medical GmbH), study-specific, but routine procedures.~* MRI: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage.
Study NCT06539364 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life surveys were conducted
Description: Quality of life surveys were conducted with OHIP-14, OHRQoL-UK and VAS
Study NCT06539364 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quality of life surveys were conducted
Description: Quality of life surveys were conducted with OHIP-14, OHRQoL-UK and VAS
Study NCT01165684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.~Doses individually adjusted.
Study NCT01165684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Insulin aspart added before each main meal. Doses individually adjusted.
Study NCT01165684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
Study NCT01165684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
Study NCT00654706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: Once daily oral dose. Day 1-20: 4-16 mg/day (titration period). Day 21-84: 12, 16 or 20 mg/day (flexible treatment period).
Study NCT00654706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Twice daily oral dose. Day 1-20: 50-500 mg/day (titration period). Day 21-84: 400, 500 or 600 mg/day (flexible treatment period).
Study NCT01100593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: length of IV catheter
Description: Subjects will be randomized to one of two IV catheter lengths
Study NCT04520997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Up to 2 ml of Restylane Defyne per NLF and ML at baseline, up to 2 ml of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at week 3 and optional touch-up of up to 2 ml per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
Study NCT01839084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
Study NCT01839084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
Study NCT00330421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT03829826 — intervention group
Intervention type: BIOLOGICAL
Intervention: HyQvia
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Study NCT01718327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: sunitinib dose :37.5mg/day
Study NCT03098134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy
Description: Virtual Reality and Video based Exposure Therapy
Study NCT03098134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Video based health education covering common myths and false believes about dental surgeries
Study NCT00330421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00330421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00330421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00330421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative studies
Study NCT00330421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Correlative studies
Study NCT01772368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fp MDPI
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments.
Study NCT01772368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS MDPI
Description: FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.
Study NCT01772368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus
Description: ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.
Study NCT01772368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Study NCT01772368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Study NCT04524299 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chest radiation(IMRT)
Description: Patients will receive intensity modulated radiotherapy (IMRT) once a day, 5 days a week. The first stage: DT 3000 cGy / 6 FX; the second stage, DT 3500 cGy / 7 FX. Or: the first segment: DT 4000 cGy / 10 FX; the second segment DT 2400 cGy / 6 FX. The interval between two stages of radiotherapy was 4 weeks.
Study NCT04524299 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest radiation(IMRT)
Description: Patients will receive intensity modulated radiotherapy (IMRT) once a day, 5 days a week. The first stage: DT 3000 cGy / 6 FX; the second stage, DT 3500 cGy / 7 FX. Or: the first segment: DT 4000 cGy / 10 FX; the second segment DT 2400 cGy / 6 FX. The interval between two stages of radiotherapy was 4 weeks.
Study NCT04524299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy twice a week
Description: During the same period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.~1. When the radiotherapy dose was 3000 cGy / 6 FX + DT 3500 cGy / 7 FX, the infusion time was D1, D4, D8 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy.~2. When the radiotherapy dose was 4000 cGy / 10 FX + DT 2400 cGy / 6 FX, the infusion time was D1, D4, D8, D11 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy
Study NCT04524299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemotherapy once a week
Description: During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours. The infusion time was D1, D8 of the first radiotherapy and D1, D8 of the second radiotherapy.
Study NCT05676333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Study NCT02414269 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: iCasp9M28z T cell infusions
Description: Administration through the pleural catheter- On day 0 patients will be treated with genetically modified T cells. Thirty to 60 minutes before T cell infusion, patients will be given 650 mg of acetaminophen orally and 25- 50 mg of diphenhydramine orally or intravenously, to prevent infusion-related reactions. The genetically modified T cells will be infused for at least 15 minutes and no more than 2 hours through the indwelling pleural catheter depending on the volume of the T cells. A physician will be available during the infusion. Please note, during formulation of iCasp9M28z T cells, under or over estimation of CAR modified T Cells may occur. Patient may receive an altered fractionation of the total dose or up to 35% over or under total cell dose with approval of the PI. Patients who do not have enough cells to match the current dose cohort will be treated in the cohort in which they have cells available
Study NCT02414269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients will receive cyclophosphamide intravenously (at 1.5 g/m\^2)
Study NCT02414269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab will be given as 200 mg flat dose infusion intravenously.
Study NCT02891200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer support program
Description: The Peer Support Program offers education and support to participants by especially trained 'peer mentors' with oversight from a social worker.
Study NCT02891200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCP support
Description: Healthcare professional (HCP) support will be provided by a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
Study NCT02957409 — intervention group
Intervention type: DRUG
Intervention: sacubitril/valsartan
Description: This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
Study NCT01548781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impairment-based robotic intervention for reaching function
Description: All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
Study NCT01548781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impairment-based robotic intervention for reaching function
Description: All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
Study NCT04455568 — intervention group
Intervention type: DEVICE
Intervention: use EKG Wisdom bracelet
Description: Non-invasive Wearable Device (use EKG Wisdom bracelet)
Study NCT02207621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02%
Description: 1 drop once daily (QD), PM, OU
Study NCT02207621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate Ophthalmic Solution 0.5% BID
Description: 1 drop BID, AM/PM, OU
Study NCT02207621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 drop QD, AM, OU
Study NCT02207621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02% BID
Description: 1 drop BID, AM/PM, OU
Study NCT00290745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Study NCT00290745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Study NCT00290745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00290745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT01197196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Intervention
Description: Participants assigned to this condition will receive an intensive group-based lifestyle program modeled after the DPP and Look AHEAD trials. Participants will attend 16 weekly sessions involving provision of behavioral goals and strategies to modify diet and exercise behaviors in order to achieve a weight loss of at least 7% of initial body weight.
Study NCT01197196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Migraine Education
Description: Participants assigned to this condition (Healthy Living for Migraine Relief \[HLMR\]) will receive basic education and didactic instruction in migraine headaches and treatments that are the standard of care. Participants will attend 4 months of weekly group lectures focused on 3 different major topic areas: 1) migraine symptomatology and pathophysiology, 2) standard abortive and preventive pharmacological treatment options, and 3) standard and alternative non-pharmacological treatment options.
Study NCT04269499 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: QuiremSpheres®
Description: Radioembolization with QuiremSpheres® under MR imaging
Study NCT02200913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stabilization exercise
Description: core stabilization exercise, 2 times/week, 10 weeks
Study NCT02200913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: general trunk strengthening exercise
Description: general trunk strengthening exercise, 2 times/week, 10 weeks
Study NCT02804568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Oral capsule, daily administration
Study NCT01631084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JADE
Description: Patients are booked for reviews led by the doctor-nurse-HCA team every 2-4 months, preferably in a setting different from the busy clinics in order to facilitate group education and promote peer support.~Between each follow-up visit, the nurse or HCA will contact the patient by phone or email to remind them of the appointments (e.g. medical FU visit or laboratory tests), adhere to medications and healthy lifestyles, perform self glucose monitoring and provide psychosocial support, as appropriate.
Study NCT01631084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIAMOND
Description: Patients randomized to the DIAMOND group will receive usual care after the initial baseline comprehensive assessment (CA), with repeat CA at 12 and 24 months.
Study NCT02235350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Treatment (AOT)
Description: Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
Study NCT02199795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contralaterally Controlled Neuromuscular Electrical Stimulation
Study NCT02199795 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cyclic Neuromuscular Electrical Stimulation
Study NCT00831311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T
Description: 0.5 mL, Intramuscular
Study NCT00831311 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine
Description: 0.5 mL, Intramuscular (right and left thighs, respectively)
Study NCT01590043 — intervention group
Intervention type: OTHER
Intervention: Salivary samples
Description: Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.
Study NCT02235350 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Observation of videos with no motor content (MNO)
Description: Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
Study NCT01552850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 1X40 mg PF-00345439 formulation A capsule with water and under fed condition
Study NCT01552850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 1X40 mg PF-00345439 formulation B capsule with water and under fed condition
Study NCT01552850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 1X40 mg PF-00345439 formulation C capsule with water and under fed condition
Study NCT01552850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 1X40 mg PF-00345439 formulation D capsule with water and under fed condition
Study NCT01552850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
Study NCT01982240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide
Description: Plecanatide tablets QD for 12 weeks
Study NCT01982240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets QD for 12 weeks
Study NCT01982240 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bisacodyl
Description: Rescue medication
Study NCT02592382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xylitol spray
Description: xylitol nasal spray will be administered to this arm three times daily for three months
Study NCT02799966 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Myndmove
Description: 20 sessions of 1 hour treatments with the MyndMove device (functional electrical stimulation) to the muscles of the upper limb(s), conducted 3 to 5 times per week, over 4 to 7 weeks.
Study NCT00363675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional hand tests
Description: Chilren were tested after healed hand burns for functional ability.
Study NCT02425332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat gait trainer